December 1, 2020

The Niche

Knoepfler lab stem cell blog

Angelman Syndrome stem cells

1 min read

CIRM announced recently the funding of a number of exciting new studies. ViaCyte received additional funding to support its development of its hESC-based pancreatic progenitor cell product PEC-Direct clinic trials. This work is very promising. CIRM also funded additional diabetes-related research by Humacyte on engineering blood vessels for use in dialysis, which is very creative. I was happy to see that my colleague here at UC Davis School of Medicine, Professor David Segal, received funding for a cutting edge grant on using gene editing for …Read More